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 Abstract 
 Objective : Platelet endothelial aggregation receptor 1  (PEAR1 ) is a membrane protein involved in platelet contact-induced 
activation and sustained platelet aggregation. Experimental studies identifi ed  PEAR1 , as a candidate gene that may be 
linked to the blood-pressure driven kidney injury in salt-sensitive Dahl rats.  Aim : In a family-based European population 
study (mean age 39.7 years; 52.2% women), we searched for association of changes in blood pressure or incidence of 
hypertension with genetic variation in  PEAR1. Methods: Among 1973 randomly recruited people, genotyped for  PEAR1 , 
we measured blood pressure at baseline and follow-up.  Results : Median follow-up was 10.0 years. While accounting for 
family clusters and blood pressure at baseline and with adjustments applied for sex, age, body mass index, smoking and 
drinking, total cholesterol, and antihypertensive drug treatment, all associations of systolic and diastolic blood pressure 
changes with nine single nucleotide polymorphisms (SNPs) in  PEAR1 were all non-signifi cant ( p    0.059). With similar 
adjustments, the incidence of hypertension (397 cases among 1532 participants were normotensive at baseline [25.9%]) 
was not related to the SNPs in  PEAR1 (hazard ratios    1.09;  p    0.09).  Conclusion : Our study suggests that  PEAR1 is not 
a hypertension susceptibility gene in humans. 
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 Introduction 
 Platelet endothelial aggregation receptor 1 ( PEAR1 ) is 
a recently discovered membrane protein involved in 
platelet contact-induced activation (1) and sustained 
platelet aggregation (2), and is highly expressed in 
platelets and endothelial cells. Genetic variants in 
 PEAR1 are associated with increased platelet responses 
to agonists (3) and the inter-individual variability in 
the response to antiplatelet drugs (4,5). A further study 
(4) addressed the association between cardiovascular 
outcomes and genetic variation in  PEAR1 in two inde-
pendent aspirin-treated cohorts: 227 percutaneous 
coronary intervention patients and 1000 patients of 
the International Verapamil SR/Trandolapril Study 
Genetic Substudy (INVEST-GENES). In 144 white 
and 83 black patients undergoing percutaneous cor-
onary intervention (4),  A -allele carriers of rs12041331 
were more likely to experience a cardiovascular event 
or death compared with  GG homozygotes (hazard 
ratio    2.62; 95% confi dence interval, CI, 0.96 – 7.10; 
 p    0.059; and hazard ratio    3.97; 95% CI 1.10 –
 14.31;  p    0.035, respectively). In aspirin-treated 
INVEST-GENES patients (4), rs12041331  A -allele 
carriers had signifi cantly increased risk of myocardial 
infarction compared with  GG homozygotes (odds 
ratio    2.03; 95% CI 1.01 – 4.09;  p    0.048). 
 Experimental studies identifi ed  PEAR1 as a can-
didate gene that may be linked to kidney injury in the 
salt-sensitive Dahl rat (6), which developed kidney 
injury that became more severe as blood pressure rose 
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in response to salt loading. Renal biopsies revealed a 
signifi cantly lower nephron number in this strain 
compared with controls (6), suggesting a possible link 
between kidney damage and the development of 
hypertension. Furthermore, the endothelium plays a 
pivotal role in the regulation of arterial resistance 
through its sensing and paracrine function (7). We 
therefore searched for association between changes in 
blood pressure and the incidence of hypertension and 
genetic variation in  PEAR1 . 
 Methods 
 Recruitment for the Flemish Study on Environment, 
Genes, and Health Outcomes (FLEMENGHO) 
started in 1985. From 1985 to 1990 (8,9), a random 
sample of the households living in a geographically 
defi ned area of Northern Belgium was investigated 
with the goal to recruit an equal number of partici-
pants in each of six strata by sex and age (20 – 39, 
40 – 59 and    60 years). From 1996 until 2004, 
recruitment of families continued using the former 
participants as index persons. The participants were 
repeatedly followed up. In all study phases, we used 
the same standardized methods to measure blood 
pressure and to administer questionnaires. The 
European Project on Genes in Hypertension 
(EPOGH) recruited participants from 1999 to 2001 
(10,11). The EPOGH investigators applied the same 
protocol, questionnaires and follow-up procedures, 
as used in FLEMENGHO. The last follow-up exam-
ination took place from 2005 to 2008 in FLE-
MENGHO and from 2006 to 2008 in EPOGH (11). 
Both studies complied with the Helsinki Declaration 
for investigation of human subjects. Each local insti-
tutional review board approved the study protocol. 
Participants gave written informed consent. 
 At baseline and follow-up, experienced observers 
measured each participant ’ s anthropometric charac-
teristics and blood pressure, and administered the 
standardized questionnaire to collect information on 
medical history, smoking and drinking habits, and 
use of medications. At each contact, blood pressure 
was the average of fi ve consecutive auscultatory 
readings in the sitting position. Digit and number 
preference was checked at 6month intervals (10). 
Hypertension was an untreated blood pressure of at 
least 140 mmHg systolic or 90 mmHg diastolic or 
use of antihypertensive drugs. For adolescents ( n    33), 
we used the thresholds specifi ed by the European 
Society of Hypertension, which are stratifi ed by sex, 
age and height percentiles (12). 
 From 4535 subjects who initially agreed to par-
ticipate in FLEMENGHO ( n    3343) and EPOGH 
( n    1192), 65 participants were excluded because 
the baseline blood pressure measurements were 
missing), leaving 4470 subjects with a full set of 
required baseline measurements. Of these, 3085 
subjects participated in at least one follow-up exam-
ination. We excluded 1112 participants from analy-
sis, because the blood pressure measurements were 
missing ( n    40) or because their DNA was of bad 
quality ( n    115). Furthermore, 957 participants 
were not genotyped for  PEAR1 , because this gene 
was not included in a 16K custom-designed chip, 
used in addition to the Illumina 1M-Duo array and 
the 200K Cardio-Metabochip. Thus, the blood 
pressure cohort used to study change in blood pres-
sure included 1973 participants. Changes in blood 
pressure during follow-up were calculated as the 
last minus the baseline blood pressure. The hyper-
tension cohort used to study the incidence of hyper-
tension encompassed 1532 participants, who were 
normotensive at baseline. We censored subjects 
from further analysis after occurrence of the fi rst 
diagnosis of hypertension. 
 PEAR1 (size 22704 base-pairs) maps to a genomic 
area characterized by low linkage disequilibrium 
(Figure 1) on chromosome 1. We selected nine tagging 
single nucleotide polymorphism (SNPs; rs2768762, 
rs2644620, rs12566888, rs2768744, rs6671392, 
rs822441, rs11264581, rs12137505 and rs749256) 
that are in high linkage disequilibrium ( R 2    0.80) 
with  ∼ 50 SNPs, covering the entire  PEAR1 gene and 
having a minor allele frequency    1%. After extrac-
tion of genomic DNA from peripheral blood cells, the 
SNPs were genotyped using the TaqMan  ®  Open
Array  ™  Genotyping System (Life Technologies, 
Foster City, CA). All DNA samples were loaded at 
50 ng per microliter and amplifi ed on customized 
arrays following the manufacturer ’ s instructions. For 
analysis of the genotypes, we used autocalling meth-
ods implemented in the TaqMan Genotyper software 
version 1.3 (Life Technologies). Next, genotype clus-
ters were evaluated manually with the call rate set 
above 0.90. Sixteen duplicate samples gave 100% 
reproducibility. The overall call rate was 98%. 
 Statistical analysis was performed using SAS soft-
ware, version 9.3. We applied a generalization of the 
standard linear model, as implemented in the PROC 
MIXED procedure of SAS package, to investigate 
 Figure 1. Plot of the  PEAR1 gene on chromosome 1q21.3 –
 1q23.3. The  x -axis represents the physical position on the 
chromosome (build 37, hg19). The  y -axis and the line indicate 
the recombination rate. We selected nine single nucleotide 
polymorphisms (SNPs; rs number and position given) that are 
in high linkage disequilibrium ( R 2    0.80) with  ∼ 50 tagged SNPs 
denoted by vertical lines. 
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the associations between the change in blood pres-
sure over the time and explanatory variables, while 
accounting for relatedness among study participants 
and adjusting for covariables. A multivariable-
adjusted Cox model was performed to study the inci-
dence of hypertension in the population. 
 Results 
 The blood pressure cohort ( n    1973) included 
1029 (52.2%) women. All participants were white 
Europeans. Age averaged (   SD) 39.7 years (range 
19.5 – 83.5). Blood pressure at enrolment averaged 
124.3    16.5 mmHg systolic and 75.7    10.5 mmHg 
diastolic. At baseline, 441 (22.4%) participants had 
hypertension, of whom 170 (38.5%) were on antihy-
pertensive drug treatment. The hypertension cohort 
consisted of the 1532 participants, who were normo-
tensive at baseline. In a randomly selected group of 
unrelated participants ( n    738), randomly selected 
from the blood pressure cohort, the frequencies of 
nine SNPs in PEAR1 did not deviate from Hardy – 
Weinberg equilibrium (0.11    p    0.99). 
 Follow-up data were available at one, two or 
three or more occasions in 3474 and 1496 partici-
pants, respectively. Median follow-up was 10.0 
years (5th – 95th percentile interval, 2.2 – 24.0 years). 
While accounting for family clusters and blood 
pressure at baseline and with adjustments applied 
for sex, age, body mass index, smoking and drink-
ing, total cholesterol, and antihypertensive drug 
treatment, the associations between change in sys-
tolic or diastolic blood pressures with the nine SNPs 
in  PEAR1 were all non-signifi cant (Table I). The 
incidence of hypertension among 1532 participants 
who were normotensive at baseline amounted to 
397 (25.9%). With adjustments applied as before, 
incident hypertension was not associated with the 
SNPs in  PEAR1 . The hazard ratios were all smaller 
than 1.09 ( p    0.09). 
 Discussion 
 We could not confi rm our working hypothesis that 
change in blood pressure over time or the incidence 
of hypertension are associated with genetic varia-
tion in  PEAR1 . The current literature data are 
based on genome-wide association studies (3) and 
further genotyping that identifi ed rs12041331 (4,5) 
as the SNP was associated with inter-individual 
variability in the responses to antiplatelet drugs and 
cardiovascular outcomes in aspirin-treated patients 
with coronary heart disease. In our current study, 
rs12566888 is a proxy of rs12041331with a D ’ 
equal to 1 and Rsq of 0.85 with a distance of 667 
base pairs. To cover the entire gene region, we 
selected in total nine tagging SNPs that are in high 
linkage disequilibrium with other known SNPs in 
 PEAR1 ( n    50). 
 Recent experimental studies identifi ed  PEAR1 as 
an active determinant of different Akt driven 
endothelial functions, ranging from endothelial cell 
proliferation, migration and ultimately tube forma-
tion. Increasing  PEAR1 expression during matura-
tion of endothelial cells progressively activates Notch 
signalling, driving angiogenesis towards completion 
(13). In 2012, compared with the spontaneously 
hypertensive rats (SHR), a major locus on chromo-
some 2 was identifi ed that increases proteinuria in 
Dahl salt-sensitive (DSS) rats (14). Williams and 
coworkers evaluated blood pressure, proteinuria and 
renal haemodynamics in congenic strains with small 
segments of the protective SHR genome on the DSS 
rat background (6). Proteinuria and renal function 
were signifi cantly improved in the congenic strains 
compared with the DSS rat. The causative locus 
interval was narrowed to less than 375 kb on the 
basis of congenic strains, haplotype data, compara-
tive mapping and concordance with human genetic 
studies (6). Sequencing of the coding region of 
genes in this region identifi ed 36 SNPs (13 non-
synonymous and 23 synonymous). Gene expression 
 Table I. Multivariable-adjusted associations between blood pressure changes and  PEAR1 single nucleotide polymorphism (SNPs). 
Major/minor 
alleles
No. with genotype 
( AA/Aa   aa) 
Effect size (95% CI)
Marker Position (bp) Location MAF Systolic pressure Diastolic pressure
rs2768762 156860462 5 ’ -fl anking  T/G 0.21 1245/728  – 0.18 ( – 0.85 to 0.49)  – 0.14 ( – 0.57 to 0.28)
rs2644620 156861168 5 ’ -fl anking  T/C 0.11 1553/420  – 0.18 ( – 0.96 to 0.61)  – 0.19 ( – 0.70 to 0.31)
rs12566888 156869047 Intron  G/T 0.10 1596/377  – 0.56 ( – 1.35 to 0.29)  – 0.17 ( – 0.70 to 0.35)
rs2768744 156872149 Intron  A/G 0.21 1239/734  – 0.32 ( – 0.99 to 0.34)  – 0.24 ( – 0.66 to 0.19)
rs6671392 156878737 Coding  T/C 0.13 1506/467 0.08 ( – 0.68 to 0.83)  – 0.20 ( – 0.68 to 0.29)
rs822441 156882996 Coding  G/C 0.16 1406/567 0.11 ( – 0.61 to 0.82) 0.12 ( – 0.34 to 0.57)
rs11264581 156883493 Coding  G/A 0.17 1366/607 0.10 ( – 0.61,0.80)  – 0.42 ( – 0.87 to 0.03)
rs12137505 156883546 Coding  A/G 0.44 1347/626  – 0.09 ( – 0.78 to 0.61) 0.01 ( – 0.43 to 0.45)
rs749256 156884365 Intron  C/T 0.22 1202/771 0.54 ( – 0.02 to 1.30)  – 0.09 ( – 0.51 to 0.33)
 All estimates accounted for family clusters and blood pressure at baseline and were adjusted for sex, age, body mass index, smoking and 
drinking, total cholesterol, and antihypertensive drug treatment. None of the  p -values for association with the SNPs reached signifi cance 
( p    0.059).  p -values refer to the signifi cance of the difference between homozygotes of the major allele (AA) versus heterozygotes and 
homozygotes of the minor allele (Aa   aa). MAF indicates minor allele frequency. To retrieve information about SNPs and their genomic 
context we used the hg19 (National Center for Biotechnology Information 37) assembly. 
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profi ling indicated that only a few genes exhibited 
differential expression, including  PEAR1 (6). The 
homologous region in humans was found to be 
associated with estimated glomerular fi ltration rate 
in the Candidate Gene Association Resource popu-
lation (6). In spite of the well-known association 
between blood pressure and renal function in 
humans (15), we could not fi nd any association with 
change in blood pressure or incidence of hyperten-
sion and genetic variation in  PEAR1 . 
 The present study must be interpreted within 
the context of its potential limitations. First, our 
sample size was relatively small and 957 partici-
pants had no  PEAR1 genotypes. Second, our fi nd-
ings were obtained in white Europeans and cannot 
be extrapolated to other ethnicities. Third, across 
our FLEMENGHO and EPOGH cohorts, we only 
assessed albuminuria, using a semi-quantitative 
dipstick method, so that we could not account for 
this covariable. However, additional adjustment of 
the mixed models (Table I) or the Cox regression 
models did not materially alter our results (data 
not shown). Finally, blood pressure at each visit 
was the average of only fi ve consecutive blood 
pressure readings. However, as reported elsewhere, 
we implemented a stringent quality assurance and 
quality control programme (10). In conclusion, 
based on our current observations in humans 
and pending confi rmation in population studies 
with larger sample size,  PEAR1 should not be 
 considered as a hypertension susceptibility gene in 
humans. 
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